---
schema_version: "secwatch.filing_event.v1"
accession: "0001628908-24-000051"
form_type: "8-K"
ticker: "EVH"
cik: "0001628908"
company_name: "Evolent Health, Inc."
filed_at: "2024-05-09T23:59:59+00:00"
generated_at: "2026-06-02T06:06:28.423371+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Evolent Health Q1 revenue $639.7M (+49.6% YoY); raises FY2024 revenue guide

## Summary
- Revenue $639.7M, net loss $(25.2)M; Adjusted EBITDA $54.1M (8.5% margin).
- Raises full-year 2024 revenue outlook; reiterates Adjusted EBITDA and exit-rate guidance.
- Ends NIA transition services agreement; partners with Careology to accelerate patient navigation.
- New Performance Suite with Molina for oncology/cardiology in SC and MS; MSK contract with east coast Medicaid plan.
- Performance Suite average lives 7,050 (up from 3,242 YoY); specialty care revenue grew over 60%.

## SEC filing metadata
- accession: 0001628908-24-000051
- form_type: 8-K
- ticker: EVH
- cik: 0001628908
- company_name: Evolent Health, Inc.
- filed_at: 2024-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1628908/000162890824000051/0001628908-24-000051-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1628908/000162890824000051/evh-20240509.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628908-24-000051
- JSON: https://secwatch.observer/filing/0001628908-24-000051.json
- Plain text: https://secwatch.observer/filing/0001628908-24-000051.txt

## Key facts
- Earnings Releases
  Evolent Health, Inc. reported the quarter ended March 31, 2024 results: revenue $639.7 million, net income $(25.2) million. Guidance raised.
  - Period: the quarter ended March 31, 2024
  - Revenue: $639.7 million
  - Net income: $(25.2) million
  - Guidance: raised
  - Result: reported results
  source text: Evolent Announces First Quarter 2024 Results • Revenue of $639.7 million, an increase of $212.0 million or 49.6%, from the three months ended March 31, 2023. • Net loss attributable to common shareholders of Evolent Health, Inc. of $(25.2) million and a net loss margin of (3.9)%.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1628908/000162890824000051/0001628908-24-000051-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.